Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Humira Prescribers for Arthritis: Rheumatologists (US)(?)

Council Members in this Study Group: 64

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Ara Dikranian, MD
Partner
San Diego Arthritis Medical Clinic

Ara Dikranian, MD, is a Rheumatologist at San Diego Arthritis Medical Clinic, a single-specialty private practice in San Diego, California. Dr. Dikranian is board certified in Internal Medicine and Rheumatology. He completed his rheumatology training at the University of California San Diego. He has...

Herbert Baraf, MD, FACP, FACR, Clinical Associate Professor of Medicine, UNIVERSITY OF MARYLANDHerbert Baraf, MD, FACP, FACR
Clinical Associate Professor of Medicine
UNIVERSITY OF MARYLAND

Herbert Baraf, MD, FACP, FACR, is the Managing Partner of Arthritis and Rheumatism Associates and the Medical Director of Center for Rheumatology and Bone Research in Maryland. He is also the Clinical Professor of Medicine at George Washington University Medical Center and Clinical Associate Professor...

Dipti Doshi, MD
Rheumatologist
HEALTHCARE PARTNERS MEDICAL GROUP

Dipti Doshi, MD, is a board certified Rheumatologist at Health Care Partners Medical group, California. Dr. Doshi is also board certified in Internal Medicine. Her special interests are in rheumatoid arthritis, lupus, pain-related to scleroderma, fibromyalgia, and osteoarthritis. Dr. Doshi is interested...

Avram Goldberg, MD,FACR, Assistant Professor , Albert Einstein College of MedicineAvram Goldberg, MD,FACR
Assistant Professor
Albert Einstein College of Medicine

Avram Goldberg, MD, FACR, is an Attending Physician at North Shore University Hospital and an Assistant Professor at the Albert Einstein College of Medicine, New York. He is part of the Division of Rheumatology where he is responsible for treatment of autoimmune and musculoskeletal diseases including...

Kenneth Nies, MD, FACP
Rheumatologist
Arthritis and Osteoporosis Treatment Center

Kenneth Nies, MD, FACP, is a Clinical Professor of Medicine at the University of California Los Angeles and is also in private practice at the Arthritis and Osteoporosis Treatment Center in Torrance, California. In addition to his clinical work, his background includes 10 years of academic medicine...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Analysis of: Drugs to Build Bones May Weaken Them | www.nytimes.com

This should not deter the practicing physician to prescribe these agents osteoporosis will reach epidemic proportions and if we can reduce fractures by 50% the savings within the healthcare system will be enormous that's not to say that individuals albeit rare may have a propensity to develop fractures...

By Dipti Doshi, MD, Rheumatologist, HEALTHCARE PARTNERS MEDICAL GROUP

Drug therapies for RA include (NSAIDS), DMARDS, and, most recently, biologics. Biologics currently on the market for RA target immune messengers called cytokines, which promote the damaging inflammatory process, and include anti-tumor necrosis factor (TNF) drugs – infliximab , etanercept,adalimumab,...

A delay in instituting aggressive antirheumatic medications such as the biologic response modifiers has long term implications in irreversible joint damage. Cost considerations (particularly with the looming potential of "universal healthcare" under a new administrations promises) with exponentially...

Analysis of: U.S. reviews osteoporosis drugs' effect on heart | www.reuters.com

 In a recent hip fracture intervention trial released on the New England Journal of Medicine website by Lyles, et al on Sept 17,2007 (not scheduled to be released in print until Nov 1 2007) Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture   A placebo controlled study...

By Dipti Doshi, MD, Rheumatologist, HEALTHCARE PARTNERS MEDICAL GROUP

Pharmacokinetic studies of Adlea showed that when it is locally administered to the site of pain, there appears to be limited systemic exposure. Its short duration of systemic exposure (hours) relative to the long duration of analgesia (12 weeks) resulting from a single treatment course of Adlea is...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Academic Institution*
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Director
  • Owner
  • Physician - Division Head
  • President
  • Partner
  • Medical Director
  • Professor

GLG's 850+ Clients Include:

Fortune 500®  companies
40 of the leading 50  global mutual funds
15 of the leading 20  global banks
8 of the leading 10  global private equity firms
5 of the top 10  AmLaw firms

Analytics


Generated at 2009-01-08T19:00:17.880